Daxor Corporation (DXR)

개요 뉴스 가격 이력 토론 예측 배당 이력

Relative Volume:

Daxor Corporation Stock (DXR) Company Profile

Daxor Corporation

Healthcare (1111)

212-330-8500

Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY

최신 SEC 제출 서류

DXR's Discussions on Twitter

Compare DXR vs ISRG, BDX, ALC, RMD, MDLN

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
DXR Daxor Corporation	11.45	67.83M	2.61M	1.69M	0	0.3003
ISRG Intuitive Surgical Inc	491.08	177.98B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	169.63	48.78B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	82.31	41.08B	10.19B	1.05B	1.38B	2.1044
RMD Resmed Inc	251.39	37.74B	5.40B	1.49B	1.78B	10.12
MDLN Medline Inc	43.84	34.80B	28.43B	1.16B	1.26B	1.4457

Daxor Corporation Stock (DXR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2019-05-16	개시	Ascendiant Capital Markets	Buy

Daxor Corporation 주식(DXR)의 최신 뉴스

Daxor Corporation (DXR) 재무 분석

Daxor Corporation (DXR)

Daxor Corporation Stock (DXR) Company Profile

Compare DXR vs ISRG, BDX, ALC, RMD, MDLN

Daxor Corporation Stock (DXR) Upgrades & Downgrades

Daxor Corporation 주식(DXR)의 최신 뉴스

DXR SEC FilingsDAXOR CORP 10-K, 10-Q, 8-K Forms - Stock Titan

Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share - marketscreener.com

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Bitget

Daxor reports 45% revenue growth, plans regulatory shift - Investing.com

Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders - marketscreener.com

Daxor (DXR) Records Strong Growth and Regulatory Changes in 2025 - GuruFocus

Daxor issues update in Letter to Shareholders - TipRanks

Daxor (DXR) Secures FDA Clearance for Advanced Blood Volume Anal - GuruFocus

Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - TradingView

7-pound blood volume analyzer wins FDA clearance, gains hospital users - Stock Titan

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - marketscreener.com

FDA clears faster blood volume test as Daxor revenue surges 45% - Stock Titan

DXR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

FDA‑cleared BVA boosts momentum; Daxor (NASDAQ: DXR) posts NAV $9.07 and $46M operating valuation - Stock Titan

Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0% - MarketBeat

Daxor Corporation (DXR) Competitors - Meyka

Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey - Defense World

EBIT per share of Daxor Corporation – NASDAQ:DXR - TradingView

Daxor (NYSEAMERICAN:DXR) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Daxor continues strategic expansion, opens new BVA program in Tennessee - TipRanks

Daxor (DXR) Expands BVA Program to Southern Middle Tennessee - GuruFocus

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - The Manila Times

Gainers Report: Will LightPath Technologies Inc benefit from government policy2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn

Daxor (NYSEAMERICAN:DXR) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Is Daxor Corporation stock a safe haven assetWeekly Profit Summary & Stock Portfolio Risk Control - mfd.ru

Can Daxor Corporation stock double in next 5 yearsTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru

Daxor to shift regulatory reporting from Investment Company Act By Investing.com - Investing.com South Africa

Winners Losers: Is Daxor Corporation a turnaround storyWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn

Daxor Corp reaffirms focus on blood volume analysis technology - marketscreener.com

Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology - TradingView

Daxor to transition to Securities Exchange Act of 1934 reporting company - TipRanks

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business - The Manila Times

Daxor Corporation Announces Transition To Securities - GlobeNewswire

Daxor (NYSEAMERICAN:DXR) Stock Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat

Trading the Move, Not the Narrative: (DXR) Edition - Stock Traders Daily

Daxor (NASDAQ:DXR) Stock Price Up 0.6%Time to Buy? - MarketBeat

Contrasting Daxor (NASDAQ:DXR) and Quest Diagnostics (NYSE:DGX) - Defense World

Aug Swings: Should I invest in Daxor Corporation before earningsPortfolio Profit Report & Safe Entry Point Alerts - baoquankhu1.vn

Guidance Update: Is Daxor Corporation a turnaround storySwing Trade & Stock Timing and Entry Methods - baoquankhu1.vn

What is the PEG ratio of Daxor CorporationOil Prices & Safe Entry Momentum Stock Tips - mfd.ru

What are Daxor Corporation’s technical support levels2025 Growth vs Value & Accurate Intraday Trading Signals - mfd.ru

Aug Outlook: Will Daxor Corporation stock go up in YEAR2025 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn

Daxor completes $8.1 million direct offering of common stock on Nasdaq - Investing.com Australia

Daxor Signs Multiple Material Agreements - TradingView

Daxor Corporation Announces $9 Million Registered Direct Offering - Sahm

Daxor Releases Updated Investor Presentation to Public Markets - The Globe and Mail

Daxor prices 765,958 shares at $11.75 in registered direct offering - TipRanks

Daxor to raise $9M in new stock sale at $11.75 a share - Stock Titan

Why is Daxor Corporation stock going downAnalyst Downgrade & Capital Efficiency Focused Ideas - bollywoodhelpline.com

Price-Driven Insight from (DXR) for Rule-Based Strategy - Stock Traders Daily

Daxor Corporation (DXR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

DXR과 유사한 종목